

Special Issue

Clinical Trials in Breast Cancer

Message from the Guest Editor

Clinical trials in oncology are still the most important method of improving our knowledge and guiding our daily clinical practice. During the last decade, the number of anticancer drugs, driven by molecularly targeted agents and immunotherapy, has grown exponentially. To date, drug innovation in oncology represents around 50% of the overall drug development in the world. Breast cancer is probably a good example of this dynamic. The aim of this Special Issue on “Clinical Trials in Breast Cancer” is to describe the current landscape of clinical trials in surgery, radiotherapy, and medical treatments, to address methodological endpoints, and to understand how biomarkers and preclinical modelling can be better integrated.

Guest Editor

Prof. Dr. Gilles Freyer

1. Medical Oncology Department, CITOHL, Hospices Civils de Lyon, 69002 Lyon, France
2. Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, 69310 Pierre-Bénite, France

Deadline for manuscript submissions

closed (31 May 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/60311

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)